Exabis Library
Welcome to the e-CCO Library!
P062: Antibody responses to SARS-CoV-2 vaccination outperform responses induced by natural infection in patients with IBD receiving immunosuppressive medications: a report from the ICARUS-IBD consortium.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:48 AM
P062: Critical role of the IL-33/ST2 axis in colitis-associated colorectal cancer
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P062: Differences in immune cell population subsets in inflammatory bowel disease patients under anti-TNF treatment
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P062: Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P062: Small intestinal lactulose and sucralose hyper-permeability in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P062: The narrow spectrum kinase inhibitor TOP1288 demonstrates potent anti-inflammatory effects in a T cell adoptive transfer colitis model through a topical mode of action
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P063 B-cell receptor signalling in lymphoid tissues may be regulated by CEACAM1
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P0630: Are women with inflammatory bowel disease at risk of abnormal cervix cytology? -results of retrospective study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0631: Short-term effectiveness of risankizumab in patients with Crohn´s Disease: Experience in our centre
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0632: Analysis of serological responses to SARS-Cov-2 vaccination in patients with Inflammatory Bowel Disease in India identifies low BMI as an independent determinant of vaccine non-response
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0633: Real World Outcomes of Upadacitinib Induction Therapy for Patient with Inflammatory Bowel Disease in Korea
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0634: Upadacitinib Effectiveness And Safety In Patients With Ulcerative Colitis: Data From A Real-World Study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0635: Degree of interest in using a cognitive-behavioral therapy application for fatigue management and related factors among outpatients with inflammatory bowel disease
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0636: Impact of obefazimod treatment on histologic and combined histologic and endoscopic outcomes in patients with moderately to severely active ulcerative colitis: results from the Phase 2b open-label maintenance study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0637: Ebrasodebart (Ent001) First in Human trial in healthy volunteers: pharmacokinetic results and predicted therapeutic concentrations to preserve mucosal healing in patients with Ulcerative Colitis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0638: Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn’s disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P0639: Population pharmacokinetics of subcutaneous vedolizumab in Crohn’s disease and Ulcerative Colitis
2025
ECCO'25
Monday, 10 February 2025, 2:00 PM
P063: Dissecting the role of rage in intestinal fibrosis
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P063: Expression of the coinhibitory receptor TIGIT on memory CD4+ T cells is induced by TCR ligation and retinoic acid co-stimulation and is elicited during microbial colonization of the intestine.
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P063: Faecal calprotectin as a non-invasive treatment target to predict mucosal healing and histological remission in asymptomatic ulcerative colitis
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM